Peptides9 min read
What the July 2026 FDA peptide hearing changes
The July 2026 peptide hearing concerned a compounding list. Its reported recommendation, FDA's scientific review and drug approval are different decisions.
Read articleBlog
Research, explained. Explore peptides, supplements, hormone health, longevity and red light therapy with clear, practical breakdowns of what the studies actually tell us.
Explore the articles
Find a topic you’re curious about and take a closer look.
TRT9 min read
TRT After Cancer Treatment: Why a General Safety Headline Is Not Enough
Cancer type, prior treatment and current cancer status change the TRT decision. Two survivor trials explain what symptom and body-composition benefits do—and do not—establish.
Read article
Peptides9 min read
Semaglutide and heart risk: what the SELECT trial changed
SELECT measured cardiovascular events in people with established disease. Learn what its relative and absolute results mean for treatment decisions.
Read article
HRT8 min read
The 2026 HRT label changes: what changed, and what still matters
FDA revised warnings for six menopause products. Here is how to understand the changes, retained risks and differences between systemic and local therapy.
Read article
HRT8 min read
Bleeding on HRT: what NICE's 2026 update means for your next step
NICE's updated bleeding timeline helps frame an HRT review. Learn why regimen, bleeding pattern and medical history matter alongside ultrasound or biopsy.
Read article
HRT9 min read
Menopause Brain Fog: Why Dementia-Prevention Claims Go Too Far
Menopause brain fog, cognitive test scores and dementia are different outcomes. Learn what the trials and 2026 label changes actually show.
Read article
HRT9 min read
Testosterone for women: desire, energy and strength are different questions
Testosterone has evidence for a defined sexual-health problem, but claims about energy, cognition and strength require separate answers.
Read article
HRT9 min read
HRT after breast cancer: why local and systemic treatment need separate discussions
Local vaginal estrogen and systemic HRT raise different questions after breast cancer. Understand recurrence findings, mortality data and endocrine treatment.
Read article
HRT9 min read
The hormone-panel trap in perimenopause
A normal hormone result does not rule out perimenopause. Learn why timing matters, when tests help and how targeted assessment differs from hormone panels.
Read article
HRT9 min read
Does everyone need to stop HRT at 65?
Age 65 is not an automatic HRT stopping point. Explore continuation versus late initiation, randomized findings and the limits of large observational studies.
Read article
Peptides9 min read
Oral semaglutide and injections: why milligrams don't tell the whole story
A tablet’s milligrams are not an injection equivalent. Follow the absorption research to understand why formulation, food and dosing conditions matter.
Read article
Peptides8 min read
Was sermorelin FDA-approved? Understanding Geref and today's products
Geref had specific historical approvals. Understand their withdrawal, FDA's later determination and why a compounded sermorelin product has a separate status.
Read article98–109 of 600 articles